- Statement of Changes in Beneficial Ownership (4)
November 04 2008 - 4:44PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
January 31, 2008
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
WEISS MICHAEL S
|
2. Issuer Name
and
Ticker or Trading Symbol
XTL BIOPHARMACEUTICALS LTD
[
XTLB
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/30/2007
|
(Street)
VALLEY COTTAGE, NY 10989
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
OPTIONS TO PURCHASE ORDINARY SHARES
|
$0.198
|
10/10/2008
|
10/10/2008
|
A
|
V
|
3500000
(1)
|
|
10/10/2008
|
10/10/2018
|
ORDINARY SHARES
|
3500000
|
$0.198
|
3500000
|
D
|
|
OPTIONS TO PURCHASE ORDINARY SHARES
|
$0.36
|
12/30/2007
|
12/30/2007
|
G
(2)
|
V
|
|
3083333
|
(3)
|
8/1/2010
|
ORDINARY SHARES
|
3083333
|
$0.36
|
9666667
|
D
|
|
Explanation of Responses:
|
(
1)
|
2,916,668 options vested on 10/10/2008. An additional 97,222 options vest monthly for a total of 583,332 additional vested
options.
|
(
2)
|
On December 30, 2007, Mr. Weiss trasnfered 3,083,333 options previously reported on a Form 3 on August 26, 2008, to Three
Jems I, LLC, a limited liability company over which Mr. Weiss exercises neither voting nor investment control. Mr. Weiss
hereby disclaims beneficial ownership of the 3,083,333 options transfered to Three Jems I, LLC.
|
(
3)
|
All of the options have vested and are exercisable.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
WEISS MICHAEL S
C/O XTL BIOPHARMACEUTICALS LTD
711 EXECUTIVE BLVD., SUITE Q
VALLEY COTTAGE, NY 10989
|
X
|
|
|
|
Signatures
|
/s/ Michael S. Weiss
|
|
11/3/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2024 to Oct 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2023 to Oct 2024